Phibro Animal Health (NASDAQ:PAHC) Given New $22.00 Price Target at Barclays

Phibro Animal Health (NASDAQ:PAHC) had its price objective lifted by investment analysts at Barclays from $20.00 to $22.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Barclays‘s price objective suggests a potential downside of 7.13% from the company’s previous close.

Several other equities research analysts also recently commented on PAHC. Morgan Stanley upped their price objective on shares of Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. StockNews.com lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, Phibro Animal Health currently has an average rating of “Hold” and a consensus target price of $21.00.

Phibro Animal Health Trading Down 3.6 %

Shares of PAHC stock opened at $23.69 on Monday. The company has a quick ratio of 1.69, a current ratio of 3.20 and a debt-to-equity ratio of 2.99. The firm has a market cap of $959.45 million, a P/E ratio of 49.35, a PEG ratio of 0.53 and a beta of 0.52. The company has a 50 day moving average of $21.90 and a 200-day moving average of $21.68. Phibro Animal Health has a 12-month low of $10.03 and a 12-month high of $25.98.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. Sell-side analysts anticipate that Phibro Animal Health will post 1.94 earnings per share for the current year.

Institutional Trading of Phibro Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Truist Financial Corp purchased a new position in shares of Phibro Animal Health during the 2nd quarter valued at $308,000. Sanctuary Advisors LLC bought a new stake in Phibro Animal Health during the second quarter valued at $481,000. SG Americas Securities LLC purchased a new position in Phibro Animal Health during the third quarter worth about $276,000. CWM LLC increased its stake in Phibro Animal Health by 190.8% in the 3rd quarter. CWM LLC now owns 6,363 shares of the company’s stock worth $143,000 after acquiring an additional 4,175 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $70,000. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.